Organs-on-Chips: Tech Progress & Regulatory Tailwinds

Microphysiological (MPS) systems are proving to be increasingly valuable for early drug discovery. By recreating human‑specific physiology—fluid flow, barrier function, multicellular interactions, and organ‑level mechanics—organ‑on‑chip models generate insight that’s difficult to obtain from traditional cell lines or animals. They support target validation research and they enable early efficacy modeling for processes like neuroinflammation, fibrosis, barrier breakdown, infection, and metabolic dysfunction. Liver, kidney, lung, gut, cervix, and BBB chips can also provide early tox, PK/PD, and ADME readouts; measuring metabolism, clearance, permeability, and drug–drug interactions. Beyond these core areas, chips offer windows into disease modeling, including patient‑specific biology using iPSC‑derived cells, and help de‑risk newer modalities that need human‑relevant microenvironments to behave predictably. Together, these capabilities make MPS one of the most important emerging tools for building human biology into discovery from the start, not just for avoiding late‑stage toxicology failures.

The panel will discuss the progress being made in these key areas and provide insight into the future of organ-on-chip model research. Register for free today.